Indication
Dystrophic Epidermolysis Bullosa
2 clinical trials
1 product
Product
Beremagene GeperpavecClinical trial
Open Label Treatment of Beremagene Geperpavec (B-VEC)Status: Completed, Estimated PCD: 2023-07-31
Clinical trial
A Phase III Efficacy and Safety Study of Beremagene Geperpavec (B-VEC, Previously "KB103") for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)Status: Completed, Estimated PCD: 2021-10-29